融捷健康(300247) - 2017 Q3 - 季度财报

Financial Performance - Operating revenue for the reporting period was ¥308,876,812.69, representing a significant increase of 155.62% year-on-year[7]. - Net profit attributable to shareholders was ¥15,730,220.79, a decrease of 10.93% compared to the same period last year[7]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥14,137,955.57, an increase of 33.75% year-on-year[7]. - Basic earnings per share for the reporting period was ¥0.0195, down 20.41% compared to the same period last year[7]. - The weighted average return on net assets was 0.67%, a decrease of 44.17% compared to the same period last year[7]. - Total operating revenue for the third quarter reached CNY 308,876,812.69, a significant increase from CNY 120,834,945.72 in the previous period[34]. - Net profit for the quarter was CNY 14,673,470.33, down from CNY 17,093,284.15 year-over-year[35]. - The net profit attributable to the parent company was CNY 15,730,220.79, compared to CNY 17,661,137.57 in the previous year[35]. - Basic and diluted earnings per share were both CNY 0.0195, compared to CNY 0.0245 in the same period last year[36]. - Net profit attributable to the parent company was ¥50,190,927.49, up from ¥32,987,943.62 in the previous period, reflecting a growth of approximately 52.2%[43]. - Total comprehensive income for the current period was ¥56,395,130.02, compared to ¥37,370,082.99 in the previous period, an increase of approximately 51.1%[44]. Assets and Liabilities - Total assets at the end of the reporting period reached ¥2,929,728,399.43, an increase of 2.48% compared to the end of the previous year[7]. - Total liabilities rose from ¥512,385,500.75 to ¥555,232,333.98, an increase of approximately 8.3%[28]. - The company's equity attributable to shareholders increased from ¥2,327,244,577.60 to ¥2,362,836,765.14, a growth of about 1.5%[29]. - The company's short-term borrowings decreased from ¥171,036,592.09 to ¥162,813,440.81, a reduction of about 7.1%[28]. - The company reported a total asset value of CNY 2,487,217,100.55, slightly down from CNY 2,499,944,120.04 at the end of the previous period[32]. - Total liabilities were CNY 294,166,636.02, a marginal increase from CNY 290,261,859.14[32]. - The company's equity totaled CNY 2,193,050,464.53, down from CNY 2,209,682,260.90 in the previous period[32]. Cash Flow - The company reported a net cash flow from operating activities of ¥1,387,094.41, which represents a decline of 103.12% year-on-year[7]. - The cash inflow from operating activities totaled CNY 983,711,854.38, compared to CNY 355,537,342.32 in the previous period, representing an increase of approximately 176%[50]. - The net cash flow from operating activities was CNY 1,387,094.41, a significant improvement from a net outflow of CNY 44,455,878.99 in the same period last year[50]. - The cash outflow from investing activities was CNY 51,620,698.12, compared to CNY 146,412,494.53 in the previous period, indicating a decrease of about 65%[51]. - The net cash flow from financing activities was negative at CNY -58,464,852.89, compared to CNY -8,687,325.32 in the previous period, reflecting a worsening situation[51]. - The total cash and cash equivalents at the end of the period stood at CNY 284,737,618.14, down from CNY 251,777,464.43 in the previous period[52]. - The company experienced a net decrease in cash and cash equivalents of CNY -92,299,475.00, compared to a decrease of CNY -66,599,359.78 in the previous period[51]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 58,315[11]. - The top ten shareholders held a combined 49.09% of the company's shares, with the largest shareholder holding 14.44%[11]. - The total number of shares subject to lock-up restrictions is 314,487,011, with 10,506,000 shares currently under lock-up[17]. - The company has a total of 87,134,100 shares held by executives, with a 25% annual release of lock-up during their tenure[15]. - The company plans to partially lift lock-up restrictions on several executives' shares on December 5, 2017, including 14,000,000 shares held by Chen Wei[15]. - The report indicates that 6,396,400 shares are subject to lock-up due to equity incentives and management restrictions[17]. - The company has a total of 19,140,000 shares held by executive Ma Shao Qin, with a 25% annual release of lock-up during their tenure[15]. - The company has a total of 4,140,000 shares held by executive Wang Yan, with a 25% annual release of lock-up during their tenure[15]. - The report indicates that 3,888,889 shares held by Huang Xiaoxia are subject to lock-up restrictions, with a partial release scheduled for December 5, 2017[15]. - The report highlights that 9,650,053 shares are held by Anhui Wantou Industrial Investment Co., Ltd., which will also see a release of lock-up on December 5, 2017[17]. Operational Metrics - Operating costs amounted to CNY 291,708,757.61, compared to CNY 112,471,612.70 in the same period last year[34]. - The company's cash and cash equivalents decreased from ¥377,037,093.14 to ¥284,737,618.14, a decline of approximately 24.6%[26]. - Accounts receivable increased significantly from ¥279,444,775.47 to ¥396,024,595.24, representing a growth of about 41.9%[26]. - Inventory rose from ¥261,134,244.41 to ¥315,463,607.62, marking an increase of approximately 20.8%[26]. - The company's other receivables increased from ¥208,276,076.61 to ¥236,524,676.96, representing a growth of approximately 13.5%[26]. - The company's retained earnings increased from ¥252,251,499.14 to ¥278,301,920.19, reflecting a growth of about 10.3%[29]. - The total operating costs for the current period were ¥710,017,912.80, up from ¥308,966,747.43, which is an increase of about 130.0%[41]. - Investment income decreased to ¥9,877,687.93 from ¥14,735,201.51, a decline of approximately 32.0%[43]. - Tax expenses for the current period were ¥11,147,996.94, compared to ¥4,691,075.06 in the previous period, representing an increase of about 137.5%[43]. Future Outlook - Future outlook includes potential market expansion and new product development, although specific details were not provided in the current report[44].